Dual-action drug produces shows promising results in neuroendocrine tumor trial

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

Related Keywords

Madrid ,Spain ,United States ,Jennifer Chan ,Jeffrey Meyerhardt ,Lily Ramsey ,Rectal Cancer Center At Dana Farber ,Dana Farber Cancer Institute ,Cancer Therapy Evaluation Program ,Congress On ,National Clinical Trials Network ,Alliance For Clinical Trials In Oncology ,European Society For Medical Oncology ,National Cancer Institute ,National Institutes Of Health ,Drug Administration ,Program In Carcinoid ,Neuroendocrine Tumors ,European Society ,Medical Oncology ,Rectal Cancer Center ,National Institutes ,Clinical Trials ,Therapy Evaluation Program ,Double Blinded Study ,Cabozantinib Versus Placebo ,Advanced Neuroendocrine Tumors ,After Progression ,Prior Therapy ,Victoria Warren ,Dana Farber News ,Blood ,Blood Vessel ,Dancer ,Arcinoma ,Fell ,Children ,Clinical Trial ,Colon ,Wood ,Hospital ,Ncology ,Pancreas ,Placebo ,Eceptor ,Humor ,